97 related articles for article (PubMed ID: 28315538)
21. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
23. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
Dang CT
Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859
[TBL] [Abstract][Full Text] [Related]
24. Taxanes in the treatment of early breast cancer.
Ring AE; Ellis PA
Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787
[TBL] [Abstract][Full Text] [Related]
25. Impact of a scientific presentation on community treatment patterns for primary breast cancer.
Giordano SH; Duan Z; Kuo YF; Hortobagyi GN; Freeman J; Goodwin JS
J Natl Cancer Inst; 2006 Mar; 98(6):382-8. PubMed ID: 16537830
[TBL] [Abstract][Full Text] [Related]
26. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
[TBL] [Abstract][Full Text] [Related]
27. [Taxanes in neojuvant radio-, chemoradio- and chemotherapy for breast cancer].
Bozhok AA; Semiglazov VF; Kletzel' AE; Arzumanov AS; Mel'nikova OA; Paltuev RM; Ivanova OA; Semiglazov VV
Vopr Onkol; 2006; 52(1):7-14. PubMed ID: 16715697
[No Abstract] [Full Text] [Related]
28. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
[TBL] [Abstract][Full Text] [Related]
29. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
30. [Taxanes as adjuvants in breast cancer. What repercussions will this have in clinical practice?].
Mosconi AM; Montedoro M
Suppl Tumori; 2004; 3(4):S18-20. PubMed ID: 15206203
[No Abstract] [Full Text] [Related]
31. Taxanes in elderly breast cancer patients.
Wildiers H; Paridaens R
Cancer Treat Rev; 2004 Jun; 30(4):333-42. PubMed ID: 15145508
[TBL] [Abstract][Full Text] [Related]
32. Evolution of taxanes in the treatment of metastatic breast cancer.
Binder S
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():9-14. PubMed ID: 23360698
[TBL] [Abstract][Full Text] [Related]
33. [Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma].
Komatsubara K; Miyoshi K; Kogure Y; Matsuhisa T; Eguchi H
Gan To Kagaku Ryoho; 2010 Jan; 37(1):107-10. PubMed ID: 20087041
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of a Standardized Premedication and Therapeutic Drug Monitoring Protocol for Pegaspargase to Prevent Hypersensitivity Reactions.
Babcock KJ; Kinnunen A; Egelund T; Ng JS; Joyce MJ
J Pediatr Pharmacol Ther; 2022; 27(3):232-236. PubMed ID: 35350153
[TBL] [Abstract][Full Text] [Related]
35. Adjunct Histamine Blockers as Premedications to Prevent Carboplatin Hypersensitivity Reactions.
Mach CM; Lapp EA; Weddle KJ; Hunter RJ; Burns KA; Parker C; Brown J; Smith JA
Pharmacotherapy; 2016 May; 36(5):482-7. PubMed ID: 26990212
[TBL] [Abstract][Full Text] [Related]
36. Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?
Schwartz JR
J Oncol Pharm Pract; 2012 Jun; 18(2):250-6. PubMed ID: 21807762
[TBL] [Abstract][Full Text] [Related]
37. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
38. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
39. [Use of pertuzumab and docetaxel desensitization in oncological patient; apropos of a case].
Guerrero Bautista R; Chica Marchal A; García Simón MS; Ferris Villanueva E; Pérez Cañadas P; De Andrés Bautista M
Farm Hosp; 2014 Nov; 38(6):491-3. PubMed ID: 25542663
[No Abstract] [Full Text] [Related]
40. Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes.
Kucukoztas N; Oguz A; Rahatli S; Altundag O; Altundag K
J BUON; 2016; 21(5):1076-1081. PubMed ID: 27837607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
